Results 11 to 20 of about 7,921 (224)
Lacosamide Increases Absence Seizures and Anxiety-Like Behavior in WAG/Rij Rat Model
Archives of Epilepsy, 2022 Objective:The aim of the present study was to evaluate the effects of antiepileptic drug lacosamide on spontaneous absence seizures and anxiety in genetic absence-epilepsy WAG/Rij rats.Methods:Tripolar electrodes were placed in the cortex of WAG/Rij rats
Orhan Sümbül +2 more
doaj +2 more sources
Unmasking of myoclonus by lacosamide in generalized epilepsy [PDF]
Epilepsy and Behavior Case Reports, 2017 Lacosamide is a new-generation antiseizure medication that is approved for use as an adjunctive treatment and monotherapy in focal epilepsy. Its use in generalized epilepsy, however, has not been adequately evaluated in controlled trials.
Daniel Birnbaum, Mohamad Koubeissi
doaj +2 more sources
Nature Reviews Drug Discovery, 2008 In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.
PERUCCA, EMILIO +3 more
openaire +4 more sources
Lacosamide for the prevention of partial onset seizures in epileptic adults
Neuropsychiatric Disease and Treatment, 2010 Anna Kelemen1, Péter Halász21National Institute of Neurosciences, Epilepsy Center, Budapest, Hungary; 2Faculty of Information Technology, Pázmány Péter Catholic University, Budapest, Hungary Abstract:
Anna Kelemen +1 more
doaj +1 more source
The Role of Add-On Lacosamide Therapy in the Treatment of Focal Onset Epilepsy
Archives of Epilepsy, 2017 Objectives:The aim of this study was to retrospectively evaluate the efficacy and safety of lacosamide (200-300-400 mg/day) as adjunct treatment in patients with uncontrolled focal-onset seizures taking 2 or more antiepileptic drugs (AED).Methods:The ...
Güray KOÇ +4 more
doaj +2 more sources
Therapeutics and Clinical Risk Management, 2018 Ebru Apaydin Doğan,1 Umuttan Doğan,2 Emine Genç,3 Çağla Erdoğan,1 Bülent Oğuz Genç3 1Department of Neurology, School of Medicine, Akdeniz University, Antalya, Turkey; 2Department of Cardiology, School of Medicine, Akdeniz ...
Doğan EA +4 more
doaj +1 more source
Enantiomeric Separation of Colchicine and Lacosamide by Nano-LC. Quantitative Analysis in Pharmaceutical Formulations [PDF]
Separations, 2020 A chiral analytical methodology was developed by nano-liquid chromatography (nano-LC) enabling the enantiomeric separation of two chiral drugs, lacosamide (novel antiepileptic drug) and colchicine (antiuremic drug), commercialized as pure enantiomers.
Natalia Casado +3 more
doaj +2 more sources
Non-Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof-of-Concept Study. [PDF]
Clin Pharmacol TherAccurate assessment of systemic drug exposure in humans remains challenging, as conventional approaches rely on intermittent blood sampling and laboratory‐based assays that are invasive and provide limited temporal resolution. Exhaled breath contains volatile and semi‐volatile compounds arising from drug metabolism and downstream biological processes ...
Fricke K +12 more
europepmc +2 more sources
Neuropsychiatric Disease and Treatment, 2013 Vanessa Delgado Nunes,1 Laura Sawyer,2 Julie Neilson,1 Grammati Sarri,1 J Helen Cross3,4 1National Clinical Guideline Centre, Royal College of Physicians, London, UK; 2Symmetron Limited, Elstree, UK; 3UCL Institute of Child Health, Great Ormond Street ...
Delgado Nunes V +4 more
doaj +1 more source
Neurotherapeutics, 2007 Lacosamide is a new chemical entity being investigated as an adjunctive treatment for epilepsy, as well as monotherapy for diabetic neuropathic pain. Lacosamide appears to have a dual mode of action: selective enhancement of sodium channel inactivation and modulation of collapsin response mediator protein-2.
Pamela, Doty +3 more
openaire +2 more sources